Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287189 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
A Phase 2 study of Duchenne Muscular Dystrophy and Neuromuscular Diseases, sponsored by Satellos Bioscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 18
- Study locations
NCT07287189: Recruiting Phase 2 study of Duchenne Muscular Dystrophy and Neuromuscular Diseases, sponsored by Satellos Bioscience.
NCT07287189 is a Phase 2 study of Duchenne Muscular Dystrophy and Neuromuscular Diseases that is actively recruiting participants, run by Satellos Bioscience. The registered enrollment target is 51 participants, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (88% lower). The trial reports 18 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07287189, a Phase 2 study of Duchenne Muscular Dystrophy and Neuromuscular Diseases, is actively recruiting participants, sponsored by Satellos Bioscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 18
- Study locations
Study Summary
Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
Primary Outcome
Occurrence of treatment emergent adverse events and relationship to investigational product
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SAT-3247
Study Locations (18)
Other
- Clinic of Neurology and Psychiatry for Children and Youth - Belgrade
- University Children's Clinic Tirsova - Belgrade
- Mother and Child Health Care Institute - Belgrade
California
- University of California Los Angeles - Los Angeles
Colorado
- Colorado Children's - Aurora
Illinois
- Lurie Children's - Chicago
Kansas
- University of Kansas - Kansas City
Maryland
- Kennedy Krieger Institute - Baltimore
Massachusetts
- UMass Memorial Medical Center - Worcester
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
What NCT07287189 shows while recruiting
NCT07287189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (88% lower).
The record links to 5 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07287189 lists 18 locations in 16 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT07287189 about?
NCT07287189 is a clinical study titled "Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients". Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
What is the current status of trial NCT07287189?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2025-12-08. Estimated completion is 2027-06-30.
What conditions does trial NCT07287189 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, Neuromuscular Diseases, Muscular Dystrophies, DMD, Duchenne.
What interventions are being tested in trial NCT07287189?
The interventions under investigation include: Placebo (DRUG), SAT-3247 (DRUG).
Who is sponsoring clinical trial NCT07287189?
This trial is sponsored by Satellos Bioscience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07287189 being conducted?
This trial has 18 study locations across California, Colorado, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07287189's enrollment target sits among peer trials
51 24th of 48 higher than 25 of 48 other Duchenne Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
RECRUITING · Phase 2
-
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Vasodilator and Exercise Study for DMD (VASO-REx)
RECRUITING · Phase 2
-
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI